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________________________________________________________________________________ 
Abstract 
3-Aminobenzanthrone (3-ABA) is the metabolite of the carcinogenic air pollutant 3-
nitrobenzanthrone (3-NBA). 3-ABA was investigated for its ability to induce cytochrome P450 1A1 
(CYP1A1) and NAD(P)H:quinone oxidoreductase (NQO1) in kidney and lung of rats, and for the 
influence of such induction on DNA adduct formation by 3-ABA and 3-NBA. NQO1 is the enzyme 
that reduces 3-NBA to N-hydroxy-3-aminobenzanthrone (N-OH-3-ABA) and CYP1A enzymes 
oxidize 3-ABA to the same intermediate. Both compounds activated by cytosolic and and/or 
microsomal fractions isolated from rat lung, the target organ for 3-NBA carcinogenicity, and 
kidney, generated the same DNA adduct pattern, consisting of five adducts. When pulmonary 
cytosols isolated from rats that had been treated i.p. with 40 mg/kg bw of 3-ABA were incubated 
with 3-NBA, DNA adduct formation was up to 1.7-fold higher than in incubations with cytosols 
from control animals. This increase corresponded to an increase in protein level and enzymatic 
activity of NQO1. In contrast, no induction of NQO1 expression by 3-ABA treatment was found in 
the kidney. Incubations of 3-ABA with renal and pulmonary microsomes of 3-ABA-treated rats led 
to an increase of up to a 4.5-fold in DNA adduct formation relative to controls. The stimulation of 
DNA adduct formation correlated with the higher protein expression and activity of CYP1A1 
induced by 3-ABA. These results show that by inducing lung and kidney CYP1A1 and NQO1, 3-
ABA increases its own enzymatic activation as well as that of the environmental pollutant, 3-NBA, 
thereby enhancing the genotoxic and carcinogenic potential of both compounds.  
________________________________________________________________________________ 
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1. Introduction 
3-Aminobenzanthrone (3-ABA, Fig. 1) is the reduced metabolite of the carcinogenic 
environmental pollutant, the nitroketone 3-nitrobenzanthrone (3-nitro-7H-benz[de]anthracen-7-one, 
3-NBA, Fig. 1) [1,2]. In recent years 3-NBA has received much attention due to its presence in 
diesel exhaust and its extremely high mutagenic potency in the Salmonella Ames assay [3-5]. 3-
NBA is carcinogenic in rats, causing lung tumours after intratracheal instillation, and it is also a 
suspected human carcinogen [4-6]. The uptake of 3-NBA in humans has been demonstrated by the 
detection of its metabolite 3-ABA in urine samples of salt mine workers occupationally exposed to 
diesel emissions [4]. 3-ABA was also the main metabolite of 3-NBA formed in human fetal 
bronchial cells and rat lung alveolar type II cells [7]. In addition, 3-ABA was found suitable for 
dyeing microporous polyethylene films, which are widely used for practical purposes such as 
separation of liquid mixtures, in particular, as separation membranes in chemical batteries [8], or to 
fluorescently label phospholipid membranes in the form of its N-palmitoyl derivative [9]. This 
suggests its industrial and/or laboratory utilization, leading to a putative exposure of people. This is 
a matter of concern, because we have demonstrated the genotoxicity of both 3-NBA and 3-ABA by 
the detection of specific DNA adducts formed in vitro and in vivo [10-17]. The predominant DNA 
adducts formed from 3-NBA and 3-ABA are 2-(2’-deoxyguanosin-N2-yl)-3-aminobenzanthrone 
(dG-N2-ABA) and N-(2’-deoxyguanosin-8-yl)-3-aminobenzanthrone (dG-C8-N-ABA) and these are 
most probably responsible for the induction of GC to TA transversion mutations induced by these 
toxicants [15,17-19].  
Recently we have demonstrated the role of rat hepatic, pulmonary and renal NAD(P)H:quinone 
oxidoreductase (NQO1) in reducing 3-NBA to species that are further activated by N,O-
acetyltransferases (NATs) and sulfotransferases (SULTs) to form DNA adducts [13,20,21]. These 
enzymes are also the major activation enzymes for 3-NBA in human liver [13]. Cytochromes P450 
(CYP) 1A1 and 1A2 are essential for the oxidative activation of 3-ABA in human and rat livers, 
leading to the same DNA adducts that are formed in vivo by 3-ABA or 3-NBA [12]. CYP1A1 is 
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also an efficient activator of 3-ABA in microsomal fractions from rat kidneys and lungs, while 
prostaglandin H synthase (cyclooxygenase, COX) plays a minor role in this subcellular fraction 
[21]. Previous results also indicate that besides microsomal CYP enzymes cytosolic peroxidases 
might play a role in the oxidative activation of 3-ABA, mainly in extrahepatic tissues such as 
kidneys and lungs [14,20,21].  In in-vitro experiments, mammalian COX, lactoperoxidase (LPO) 
and myeloperoxidase (MPO) were found to be effective in activating 3-ABA [14] (Fig. 1). 
We have already shown that both 3-ABA and 3-NBA induce the major enzymes activating 
both toxins in rat livers (NQO1, CYP1A) [20], and that 3-NBA is also a potent inducer of these 
enzymes in rat lungs and kidneys [21]. Since lung is the major target of 3-NBA and its major 
metabolite 3-ABA is excreted in urine, it was important to see if 3-ABA like 3-NBA induces the 
activating enzymes in these two organs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6
2. Material and Methods 
2.1. Chemicals  
NADPH, deoxyadenosine 3’-monophospate, deoxyguanosine 3’-monophosphate, acetyl 
coenzyme A (acetyl-CoA), 3’-phosphoadenosine-5’-phosphosulfate (PAPS), menadione (2-methyl-
1,4-naphthoquinone) and calf thymus DNA were from Sigma Chemical Co (St Louis, MO, USA); 
Sudan I from BDH (Poole, UK); 7-ethoxyresorufin from Fluka Chemie AG (Buchs, Switzerland). 
Enzymes and chemicals for the 32P-postlabelling assay were obtained from sources described [22]. 
All these and other chemicals were reagent grade or better. 
2.2. Synthesis of 3-NBA and 3-ABA 
 3-NBA and 3-ABA were synthesized as described [23] and their authenticity was confirmed by 
UV spectroscopy, electrospray mass spectrometry and high field proton NMR spectroscopy.  
2.3. Animal experiments 
 The study was conducted in accordance with the Regulations for the Care and Use of 
Laboratory Animals (311/1997, Ministry of Agriculture, Czech Republic), which is in compliance 
with Declaration of Helsinki. Male Wistar rats (100-125 g, n=3 per group) were treated with a 
single i.p. dose of 0.4, 4 or 40 mg/kg bw of 3-ABA (dissolved in sunflower oil at a concentration of 
0.4 or 4 mg/ml). Three control animals received an equal volume of sunflower oil only. Rats were 
placed in cages in temperature and humidity controlled rooms. Standardised diet and water were 
provided ad libitum. The animals were killed 24 hours after treatment by cervical dislocation. Lungs 
and kidneys were removed immediately after death and used for isolation of mRNA and for 
preparation of microsomal and cytosolic fractions.  
2.4. Preparation of microsomal and cytosolic fractions  
Microsomal and cytosolic fractions were isolated from the lungs and kidneys of rats, either 
uninduced or pretreated with 3-ABA (see above) as described [24,25].  
2.5. Cytosolic incubations  
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The deaerated and argon-purged incubation mixtures, in a final volume of 750 µl, consisted of 
50 mM Tris-HCl buffer (pH 7.4), containing 0.2% Tween 20, cofactors for cytosolic enzymes (1 
mM NADPH, 2 mM acetyl-CoA; 100 µM PAPS), pooled lung and kidney cytosolic sample from 3 
rats, treated either with vehicle (control) or with 40 mg/kg bw of 3-ABA (1 mg of cytosolic 
protein), 30 µM 3-NBA (dissolved in 7.5 µl dimethylsulfoxide) and 0.5 mg of calf thymus DNA (2 
mM dNp). The reaction was initiated by adding 3-NBA. Incubations with rat cytosols were carried 
out at 37°C for 3 hr; the cytosol-mediated 3-NBA-derived DNA adduct formation was found to be 
linear up to 4 hr [13]. Control incubations were carried out either (i) without activating system 
(cytosol), (ii) without cofactors (NADPH, acetyl-CoA, PAPS), (iii) without DNA or (iv) without 3-
NBA. After extraction with ethyl acetate, DNA was isolated from the residual water phase by the 
phenol/chloroform extraction method as described [13].  
Incubations used to evaluate the activation of 3-ABA by peroxidases in rat pulmonary and renal 
cytosolic samples contained, in a final volume of 750 µl, 50 mM Tris-HCl buffer (pH 7.4), 
containing 0.2% Tween 20, 100 µM 3-ABA (dissolved in 7.5 µl dimethylsulfoxide), 0.5 mg of calf 
thymus DNA and 200 µM hydrogen peroxide (H2O2). 
2.6. Microsomal incubations 
 Incubation mixtures, in a final volume of 750 µl, consisted of 50 mM potassium phosphate 
buffer (pH 7.4), 1 mM NADPH or 0.1 mM arachidonic acid, pooled pulmonary and renal 
microsomal fractions from 3 rats, either control or treated with 40 mg/kg bw of 3-ABA (0.5 mg of 
microsomal protein), 100 µM 3-ABA or 3-NBA (dissolved in 7.5 µl dimethylsulfoxide) and 0.5 mg 
of calf thymus DNA. The reaction was initiated by adding 3-ABA or 3-NBA and were carried out at 
37°C for 2 hr; microsomal-mediated 3-NBA (3-ABA)-derived DNA adduct formation was found to 
be linear up to 3 hr [12,26]. Control incubations were carried out either (i) without activating system 
(microsomes), (ii) with activating system and 3-ABA, but without DNA or (iii) with activating 
system and DNA but without 3-ABA. After the incubation and extraction with ethyl acetate, DNA 
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was isolated from the residual water phase by the phenol/chloroform extraction method as described 
[12].  
2.7. 32P-Postlabelling analysis and HPLC analysis of 32P-labelled 3’,5’-deoxyribonucleoside 
bisphosphate adducts 
 
32P-Postlabelling analysis using butanol extraction, thin layer chromatography (TLC) and 
HPLC was performed as described [15]. Enrichment by butanol extraction has been shown to yield 
more adduct spots and a better recovery of 3-NBA (3-ABA)-derived DNA adducts than using 
enrichment by nuclease P1 digestion [10,12]. DNA adduct spots were numbered as reported 
previously [15]. As reference compounds dAp and dGp (4 µmol/ml) (Sigma) were incubated with 
3-NBA (300 µM) activated by xanthine oxidase (1 U/ml) (Sigma) in the presence of hypoxanthine 
and analysed as described previously [10]. DNA adduct standard samples of 3-NBA, 2-(2’-
deoxyadenosin-N6-yl)-3-aminobenzanthrone-3’-phosphate (dA3’p-N6-ABA), 2-(2’-deoxyguanosin-
N2-yl)-3-aminobenzanthrone-3’-phosphate (dG3’p-N2-ABA) and N-(2’-deoxyguanosin-8-yl)-3-
aminobenzanthrone-3’-phosphate (dG3’p-C8-N-ABA), were prepared by reacting N-acetoxy-3-
aminobenzanthrone with dAp or dGp and analysed as described recently [15].   
2.8. Isolation of CYP1A1 
Recombinant rat CYP1A1 protein was purified to homogeneity from membranes of Escherichia 
coli transfected with a modified CYP1A1 cDNA [27], in the laboratory of H. W. Strobel (University 
of Texas, Medical School of Houston, Texas, USA) by P. Hodek (Charles University, Prague, 
Czech Republic).  
2.9. Preparation of antibodies  
Leghorn chicken were immunised subcutaneously three times a week with rat recombinant 
CYP1A1  and  human recombinant NQO1 (Sigma) antigens (0.1 mg/animal) emulsified in 
complete Freund’s adjuvant for the first injection and in incomplete adjuvant for boosters. 
Immunoglobulin fraction was purified from pooled egg yolks using fractionation by polyethylene 
glycol 6000 [27]. 
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2.10. Estimation of CYP1A1 and NQO1 protein content in microsomes and cytosols of rat lung and 
kidney  
Immunoquantitation of rat pulmonary and renal microsomal CYP1A1 and of cytosolic NQO1 
was done by sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis. Samples 
containing 75 µg microsomal or cytosolic proteins were subjected to electrophoresis on SDS/10% 
polyacrylamide gels [20,21,27,28]. After migration, proteins were transferred onto polyvinylidene 
difluoride membranes. Rat CYP1A1 and NQO1 proteins were probed with the chicken polyclonal 
antibodies as reported elsewhere [20,21,27,28]. The antibodies against rat recombinant CYP1A1 
and human NQO1 recognise these enzymes in rat pulmonary and renal microsomes as one protein 
band. Rat recombinant CYP1A1 (in SupersomesTM, Gentest Corp., Woburn, MA, USA) and human 
recombinant NQO1 (Sigma Chemical Co, St Louis, MO, USA) were used as positive controls to 
identify the bands of CYP1A1 in microsomes and NQO1 in cytosols. The antigen-antibody 
complex was visualised with an alkaline phosphatase-conjugated rabbit anti-chicken IgG antibody 
and 5-bromo-4-chloro-3-indolylphosphate/nitrobluetetrazolium as chromogenic substrate 
[20,21,27,28].   
2.11. CYP1A1 and NQO1 enzyme activity assays  
The microsomal samples were characterised for CYP1A1 activity using 7-ethoxyresorufin O-
deethylation (EROD) activity and the oxidation of Sudan I [27,28]. The cytosolic samples were 
characterised for NQO1 activity, using menadione (2-methyl-1,4-naphthoquinone) as a substrate 
[24,25]. NQO1 activity was determined by following the oxidation of NADPH 
spectrophotometrically at 340 nm. The standard assay system contained 25 mM Tris-HCl (pH 7.4), 
0.2% Tween 20, 0.07% bovine serum albumin, 400 mM NADPH and 100 mM menadione 
dissolved in methanol.  
2.12. CYP1A1 and NQO1 mRNA content in rat lungs and kidneys  
Total RNA was isolated from frozen lungs and kidneys of three untreated rats and three rats 
pretreated with 40 mg/kg body weight of 3-ABA using Trizol Reagent (Invitrogen, Carlsbad, CA, 
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USA) according to the procedure supplied by the manufacturer. The quality of isolated RNA was 
verified by horizontal agarose gel electrophoresis, and RNA quantity was assessed by UV-VIS 
spectrophotometry on a Carry 300 spectrophotometer (Varian, Palo Alto, CA, USA). RNA samples 
(1 µg) were reverse transcribed using 200 U of reverse transcriptase per sample with random 
hexamer primers utilising RevertAidTM First Strand cDNA Synthesis Kit (MBI Fermentas, Vilnius, 
Lithuania) according to the manufacturer's instructions. The prepared cDNA was used for real-time 
(RT) polymerase chain reaction (PCR) performed in RotorGene 2000 (Corbett Research, Sydney, 
Australia) under the following cycling conditions: incubation at 50ºC for 2 min and initial 
denaturation at 95ºC for 10 min, then 50 cycles of denaturation at 95ºC for 15 s and annealing at 
60ºC for 1 min. Gain was set to 7 and fluorescence was acquired after the elongation step. The PCR 
reaction mixtures (20 µl) contained 9 µl cDNA diluted 10-times in Milli-Q ultrapure water (Biocel 
A10, Millipore, Billerica, MA, USA), 10 µl TaqMan Universal PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA) and 1 µl TaqMan Gene Expression Assay Mix (commercially 
available unlabelled PCR primers and FAMTM dye-labelled probe for rat CYP1A1 or NQO1 as 
target genes and β-actin as reference internal standard gene). Each sample was analysed in two 
parallel aliquots. Negative controls had the same compositions as samples but cDNA was omitted 
from the mixture. Data were analysed by the program RotorGene v6 (Corbett Research, Sydney, 
Australia) and evaluated by comparative cycle threshold (cT) method for relative quantitation of 
gene expression. Cycle thresholds, at which a significant increase in fluorescence signal was 
detected, were measured for each sample. Then ∆∆cT was evaluated according to following 
equations: ∆cT = cT (target) - cT (internal standard), ∆∆cT = ∆cTtreated - ∆cTcontrol, where ∆cTtreated is 
∆cT for treated rats and ∆cTcontrol is ∆cT for untreated rats. ∆cT is positive if the target is expressed at 
a lower level than the internal standard (β-actin), and negative if expressed at a higher level. The 
induction of mRNA expression of studied target genes in pretreated animals was evaluated as 2-
(∆∆cT)
. 
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3. Results 
3.1. The effect of 3-ABA pretreatment on the expression of enzymes activating 3-NBA and 3-ABA  
Because CYP1A1 and NQO1 are the essential enzymes activating 3-ABA and 3-NBA in rat 
lungs and kidneys [24] and in rat and human livers [12,13], we evaluated whether treating rats with 
3-ABA influences their expression. Induction of these enzymes has already been found in the livers 
of rats treated with 3-ABA or the parent nitroketone, 3-NBA [20]. Western blots with chicken 
polyclonal antibodies raised against rat CYP1A1 showed that the expression of this enzyme was 
also induced in rat lung and kidney by 3-ABA (Fig. 2), whereby the induction of protein expression 
was higher in kidney than in lung (3.4-fold versus 2.5-fold at 40 mg/kg bw). EROD activity and 
oxidation of Sudan I, markers of CYP1A1 activity [27,28], were higher in both organs of rats 
treated with 3-ABA (Table 1). Again, the induction in kidney was higher than in lung (up to 4.8-
fold versus 2.5-fold at 40 mg/kg bw), although control enzyme activity in lung was only half of that 
in kidney.  
In contrast to CYP1A1, the levels of renal NQO1 protein were not increased by pretreating rats 
with 3-ABA; on the contrary lower expression levels were found in kidney cytosolic fractions of 
rats treated with 4 and 40 mg/kg bw of 3-ABA (Fig. 2). In the case of lung, NQO1 protein 
expression was increased 1.4-fold in rats treated with 40 mg/kg bw of 3-ABA. The increase in 
NQO1 activities in pulmonary cytosol depended on the administered dose and correlated with 
protein expression (Table 2 and Fig. 2). Up to a 1.6-fold increase in NQO1 activity measured with 
menadione as a substrate was found in lung of rats treated with 3-ABA (Table 2).  
Besides the evaluation of the effects of 3-ABA on protein levels and enzyme activities of 
CYP1A1 and NQO1, changes in mRNA expression levels by the compound were also investigated.  
The relative amounts of CYP1A1 and NQO1 mRNA were measured by RT-PCR. As shown in 
Table 3, treatment of rats with 40 mg/kg bw of 3-ABA increased mRNA levels of CYP1A1 and 
NQO1 in the lung and NQO1 in the kidney.  
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3.2. The effect of 3-ABA pretreatment on activation of 3-NBA by rat pulmonary and renal cytosolic 
and microsomal fractions  
Since NQO1 and CYP1A1, the enzymes relevant for 3-NBA and 3-ABA activation 
[12,13,20,21] were induced by 3-ABA, we investigated whether 3-ABA treatment increased the 
bioactivation of 3-ABA and 3-NBA by microsomal and cytosolic fractions. DNA adduct formation 
by 3-ABA and 3-NBA was measured by TLC 32P-postlabelling. 
Cytosolic samples from both organs were capable of reductively activating 3-NBA to species 
forming DNA adducts (see Fig. 3A for the renal cytosol). The DNA adduct pattern generated by 3-
NBA consisted of a cluster of up to five adducts (spots 1−5 in Figure 3) essentially identical to that 
observed in vivo in rats and mice treated with 3-NBA [10,11,13,16,17], and in in-vitro incubations 
using human and rat hepatic cytosols [13] or microsomes [26]. TLC autoradiograms of 32P-labelled 
DNA from control incubations carried out in parallel without cytosol, without DNA, or without 3-
NBA were devoid of adduct spots in the region of interest (data not shown). Cochromatographic 
analysis of individual spots on HPLC confirmed that adduct spots 1−5 that are formed with rat 
pulmonary and renal cytosols are derived from 3-NBA by nitroreduction (data not shown). Three of 
these adducts were identified, and are 2-(2’-deoxyadenosin-N6-yl)-3-aminobenzanthrone (dA-N6-
ABA; spot 1), 2-(2’-deoxyguanosin-N2-yl)-3-aminobenzanthrone (dG-N2-ABA; spot 3) and N-(2’-
deoxyguanosin-8-yl)-3-aminobenzanthrone (dG-C8-N-ABA; spots 4 and 5) [15].  
Pulmonary cytosolic samples from rats pretreated with 3-ABA (40 mg/kg bw) were more 
effective in the formation of 3-NBA-DNA adducts in the presence of NADPH, the cofactor of 
NQO1, than the pulmonary cytosol from untreated (control) rats (Fig. 4 and Supporting Table S1). 
The formation of 3-NBA-DNA adducts was 1.5-fold higher in incubations with cytosols of rats 
treated with 3-ABA relative to those of control rats. Addition of PAPS or acetyl-CoA, cofactors of 
SULTs and NATs, respectively, which enhance 3-NBA activation [13,20,24], to the incubations 
with induced cytosols had essentially the same stimulatory effects on 3-NBA adduct formation as in 
control cytosols. A 2.3- (with PAPS) and 20.3-fold (with acetyl-CoA) increase was observed in 
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comparison to the activity using NADPH alone. In renal cytosols similar effects were elicited by 3-
ABA treatment, 3-NBA-DNA adduct levels were 1.2-fold higher than in incubations with cytosols 
from control kidneys. PAPS addition led to similar increases as in lung cytosolic incubations, but 
acetyl-CoA was even more effective, leading to ~30-fold higher levels of DNA adducts both in 
cytosols from 3-ABA treated rats and in those from control rats. 
Contrary to the efficient 3-NBA activation by cytosolic reductases and conjugating enzymes, 
microsomal fractions isolated from either control or 3-ABA treated rat lungs or kidneys did not 
activate 3-NBA to DNA binding species. 
3.3. The effect of 3-ABA pretreatment on activation of 3-ABA by rat pulmonary and renal cytosolic 
and microsomal fraction 
In contrast to 3-NBA, 3-ABA was activated by lung and kidney microsomal fractions. CYP1A1 
was found to play a major role in DNA adduct formation by 3-ABA in rat lungs and kidneys [21], 
because upon addition of NADPH, a cofactor of CYPs, all pulmonary and renal microsomal 
fractions were capable of oxidizing 3-ABA to form DNA adducts (see Fig. 3B for the renal 
microsomal fractions and Supporting Table S2). Kidney and lung microsomal fractions from rats 
treated with 3-ABA (40 mg/kg bw) exhibited 4.5- and 2.8-fold higher efficiencies to activate 3-
ABA, than microsomal fractions from untreated rats, respectively (Fig. 5). Microsomal fractions 
from control and 3-ABA-treated rats also activated 3-ABA in the presence of arachidonic acid, a 
cofactor for COX-dependent oxidation [29-31] (Fig. 5 and Supporting Table S2). Autoradiograms 
of DNA digests from control incubations carried out in parallel either without microsomal fractions, 
without NADPH, without arachidonic acid, without DNA, or without 3-ABA were all devoid of 
adduct spots in the region of interest (data not shown). 
In the presence of hydrogen peroxide, a cofactor for peroxidases, pulmonary and renal cytosols 
from control (uninduced) and 3-ABA-treated rats activated 3-ABA to form DNA adducts. In 
contrast to pulmonary cytosol, by which five 3-ABA-DNA adducts (spots 1-5 in Figure 3) were 
generated, only four 3-ABA-DNA adducts (spots 1-4 in Figure 3) were detected in the renal 
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cytosolic activation system. Treatment of rats with 3-ABA slightly stimulated the formation of 3-
ABA-DNA adducts in cytosols from both organs (Fig 6 and Supporting Table S3). No adducts were 
detectable in controls without cytosols, without 3-ABA, or without hydrogen peroxide. 
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4. Discussion 
3-ABA, the human metabolite of the ubiquitous environmental pollutant 3-NBA, has been 
detected in the urine of smoking and nonsmoking salt mine workers occupationally exposed to 
diesel emissions at similar concentrations (1-143 ng/24 h urine) to 1-aminopyrene (2-200 ng/24 h 
urine), the reduced metabolite of the most abundant nitro-PAH found in diesel exhaust [4]. The 
present study was undertaken to elucidate the potential of this chemical to induce the enzymes 
responsible for its own metabolic activation (CYP1A1) and that of the parent compound 3-NBA 
(NQO1) in the kidneys and lungs of rats. The rat was used as an experimental model, because the 
same enzymes activate 3-NBA and 3-ABA in human and rat livers [12-14,16,23,26] The results 
should therefore provide some indication of what might occur in extrahepatic tissues of humans 
exposed to this pollutant. Both enzymes are known to be inducible by several agents in animals and 
humans. Human and rat CYP1A1 is induced by many compounds, e.g. polychlorinated 
hydrocarbons such as 2,3,7,8-tetrachlorodibenzo[1,4]dioxine binding to the aryl hydrocarbon (Ah) 
receptor [32], and polycyclic aromatic hydrocarbons present in cigarette smoke [33,34]. NQO1 is 
inducible by a variety of agents with different mechanisms of action (see [35] for a review), 
including tumour promoters and hydrogen peroxide [36-38].  
Expression levels and activities of NQO1 and CYP1A1 are also influenced by other factors, 
including several drugs, additional environmental chemicals and genetic polymorphisms [33,39,40]. 
So far two polymorphisms in the human NQO1 gene have been found in the general population, one 
of which is associated with an increased risk of urothelial tumours [39] and paediatric leukaemia 
[41]. The polymorphic expression of CYP1A1 has been attributed to altered expression of the Ah 
receptor, the transcription factor that modulates its regulation, or the Ah receptor nuclear 
translocator (Arnt) protein, its associated transcription factor [33,34,42]. Moreover, the CYP1A1 
gene is genetically polymorphic [33,34]. So far, CYP1A1*2A, CYP1A1*2B and CYP1A1*4 
polymorphisms  have been found that might be associated with lung, oesophageal or breast cancer 
risk and with acute myeloid leukaemia [43-46]. Thus, genetic polymorphisms in CYP1A and NQO1 
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genes could be important determinants of a possible lung cancer risk from 3-NBA and its 
metabolite 3-ABA.  
In the present study, we have shown that the expression of NQO1 and CYP1A1 proteins and 
their enzymatic activities was induced by 3-ABA in lungs of rats treated i.p. with a single dose of 
0.4, 4 or 40 mg/kg bw of 3-ABA. This induction leads to an increase in enzyme activities and, thus, 
in the potential of these enzymes to activate 3-NBA in cytosols (by NQO1) and 3-ABA in 
microsomes (by CYP1A1) to form covalent DNA adducts, thereby enhancing the first step of their 
own bioactivation. 3-ABA also efficiently induced the expression of CYP1A1, but not NQO1, in 
the kidney. This is an interesting feature emphasizing the importance of 3-ABA for induction of its 
own oxidative activation in the kidney, through which it is excreted. The concentration of 3-ABA, 
which efficiently induced both enzymes in these extrahepatic organs, was very high, 4 and 40 
mg/kg bw, and may not be relevant for human exposure levels. It was however a single dose, while 
humans are chronically exposed to low levels in certain work places in addition to cigarette smoke.  
Generally, 3-ABA is a less efficient inducer of NQO1 or CYP1A1 in rat lung and kidney than 
typical strong inducers of these enzymes binding to Ah receptor such as 1-phenylazo-2-
hydroxynaphtalene (Sudan I) [47-52] and ellipticine [53-60] or its parent nitro compound, 3-NBA 
[21]. Their potential to induce CYP1A and NQO1 enzymes in these extrahepatic rat tissues at doses 
similar to those of 3-ABA (0.4, 4 and 40 mg/kg bw) was up to 7-fold (Sudan I) [Stiborová et al., 
unpublished data] and 2-fold (3-NBA and ellipticine) [21,59,60] higher than that of 3-ABA. 
Likewise, the potency of these compounds to induce CYP1A1 was up to 6-fold higher compared to 
3-ABA. 
Induction of NQO1 and CYP1A1 mRNA levels by 3-ABA was lower than induction of proteins 
and activities of these enzymes. Similar discrepancies between induction of NQO1 and CYP1A 
mRNA and protein levels by 3-ABA were observed in rat livers [20] and also for other compounds 
as found by several authors [40,42,59,61-64]. It has been reported that some inducers might prolong 
half-lives of mRNAs, while others increase transcription. Moreover, half-lives of mRNAs are 
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usually much shorter than those of proteins [40,61,62]. A 24-h-treatment period was used in this 
study, because it was found to be an appropriate length of time to observe protein induction by 
several inducers [59,63-65]. The increase in CYP1A1 protein levels and enzyme activities reached a 
maximum at 12-20 h and then remained constant up to 24 h after treatment with a single dose of 
inducers before slowly dropping to background levels [59,63-65]. In contrast, CYP1A1 mRNA 
reached its highest level as early as 3-5 h [65-69]. 
Recently, we demonstrated that 3-ABA can be activated in vitro by N-oxidation by several 
peroxidases including MPO, LPO and COX (Fig. 1). Activation by peroxidase has also been found 
in vivo, mainly in kidneys and urinary bladders of 3-ABA-treated mice [14]. N-oxidation of 3-ABA 
finally leads to nitrenium ions that are responsible for the formation of 3-ABA-derived DNA 
adducts (Fig. 1). Whereas these ions are generated by CYP-mediated reactions via N-OH-3-ABA 
[12-14,19], peroxidases should catalyze their formation via an imino-derivative [14, 70-73]. In the 
present work we found that pulmonary and renal cytosols from rats treated with 3-ABA were more 
effective in activating 3-ABA to form DNA adducts in the presence of hydrogen peroxide than 
cytosols from control rats. The necessity for the presence of hydrogen peroxide indicates that 3-
ABA activation might be associated with an increase in peroxidase activities in pulmonary and 
renal cytosols of 3-ABA-treated rats. However, the levels of DNA adducts generated by hydrogen 
peroxide-mediated 3-ABA activation were 2-fold lower than those by pulmonary and renal 
microsomes. Collectively, these results suggest that even though peroxidases might be involved in 
3-ABA activation in these tissues, they play only a minor role.  
3-ABA delivered i.p. is absorbed via the mesenteric veins and lymphatic system, and passes 
through the liver. Thus, its concentration and effect in this tissue should be higher than in the distal 
tissues such as lung and kidney. Indeed, the induction of NQO1 and CYP1A1 proteins and 
enzymatic activities in rat liver after identical i.p. treatment was up to 6- and 2-fold higher than in 
lungs and kidneys, respectively [20, present paper].  
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The activation of the parent nitro compound 3-NBA is much more effective by cytosolic 
reductases than by microsomal enzymes and 3-NBA is a more potent genotoxic compound than its 
metabolite 3-ABA. This is reflected in the levels of total DNA adducts generated in lung 
microsomes with NADPH from 3-ABA, which are not higher than those formed from 3-NBA in 
lung cytosol without added cofactor.  
In conclusion, the results of the present study show, for the first time, that 3-ABA is capable of 
inducing NQO1 and CYP1A1 in lung and CYP1A1 in kidney of rats. These were found to be the 
predominant biotransforming enzymes involved in the metabolic activation of 3-NBA and 3-ABA, 
not only in these organs in rats [21], but also in the liver of both rats and humans [12,13,20]. 3-ABA 
also increased its own NADPH-dependent activation to DNA adducts in microsomal fractions from 
both organs, most effectively from kidneys. By such effects, 3-ABA exposure caused by its 
industrial and laboratory use or as a metabolite of 3-NBA, may lead to an enhancement of its own 
enzymatic activation, as well as that of 3-NBA, to reactive species forming DNA adducts, thereby 
enhancing the genotoxic and carcinogenic potential of both compounds.  
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Table 1   
Specific CYP1A1 activities a in kidney and lung microsomes of control and 3-ABA-treated rats 
 
 
 
CYP          Control rats                  3-ABA-treated rats [mg/kg bw] 
                  ________________  ______________________________________________________      
activity      Kidney     Lung                            Kidney                                           Lung 
                                                       0.4               4               40              0.4               4                40 
                                                       
 
EROD      9.4±0.4    4.6±0.5    20.0±0.5** 39.6±0.9*** 45.0±2.5***  5.1±0.5      6.4±0.4) *   11.5±0.8** 
                                                    (2.1)               (4.2)                 (4.8)               (1.1)                 (1.4 )               (2.5) 
   
  
Sudan I     9.3±1.0    4.7±0.5   21.8±1.2**  21.9±0.9** 34.5±1.9***   4.7±0.5      6.2±0.3*    10.9±0.7** 
oxidation                                      (2.3)                (2.3)                (3.7)                 (1.0)               (1.3)                 (2.3) 
 
 
aEach value (pmol of reaction product per min per mg protein) represents the mean ± S.E. of 
triplicate measurements. Numbers in parentheses represents the fold increase over the control 
activity caused by the pretreatment with 3-ABA (0.4, 4 or 40 mg/kg bw). 
*Significantly different from controls: p<0.05 (Student’s t-test). 
**Significantly different from controls: p<0.01 (Student’s t-test). 
**Significantly different from controls: p<0.001 (Student’s t-test). 
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Table 2 
NQO1 specific activity in rat renal and pulmonary cytosol 
 
 
 
            Control rats        3-ABA-treated rats [mg/kg bw]  
                                                           0.4                              4                                40 
 
 
Kidney          0.09 ± 0. 01      0.08 ± 0. 01    0.10 ± 0. 01                 0.10 ± 0. 01        
                                                         (0.9)                      (1.1)                            (1.1) 
   
  
Lung           0.05 ± 0.01            0.06 ± 0.01*               0.07 ± 0.01*     0.08 ± 0.01**  
                                                         (1.2)                                        (1.4)                             (1.6) 
 
 
The results (units) are averages and S.E. of five parallel measurements. Enzyme activities with 
menadione as a substrate was assayed as described in Materials and Methods. One unit of NQO1 
reduces 1 µmol of NADPH per min/mg protein at 37°C. Numbers in parentheses represents the 
fold increase over the control activity caused by the pretreatment with 3-ABA (0.4, 4 or 40 mg/kg 
bw). 
*Significantly different from controls: p<0.05 (Student’s t-test). 
**Significantly different from controls: p<0.01 (Student’s t-test). 
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Table 3 
Expression of mRNA of CYP1A1 and NQO1 
___________________________________________________________________________ 
                                                                 CYP1A1                                   NQO1                     
                                                       ∆cT
a
                                
Fold                  ∆cT                           Fold               
                                                                                   Changeb                                   Change                    
___________________________________________________________________________                                                  
Control rats                                   
Kidney                                       4.45 ± 0.36                   -                9.37 ± 0.67               -         
Lung                                        10.48 ± 0.16                   -                5.44 ± 0.34                -         
 
3-ABA-treated rats 
Kidney                                       4.49 ± 0.06                  1.0              9.07 ± 0.22*              1.2                  
Lung                                         10.02 ± 0.10**              1.4              4.97 ± 0.11**             1.4 
___________________________________________________________________________ 
 
aResults shown are mean ± S.D. from data found for three rats (control and treated with 40 mg/kg 
bw of 3-ABA).  
bThe induction of mRNA expression of studied target genes in pretreated animals (fold change) was 
evaluated as 2-(∆∆cT). 
*Significantly different from controls: p<0.05 (Student’s t-test). 
**Significantly different from controls: p<0.01 (Student’s t-test)
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Legends to Figures 
Fig. 1. Pathways of metabolic activation and DNA adduct formation of 3-NBA and 3-ABA. 
See text for details. NQO1, NAD(P)H:quinone oxidoreductase; NAT, N,O-
acetyltransferases; SULT, sulfotransferase; COX-1, cyclooxygenase 1; CYP, 
cytochrome P450; LPO, lactoperoxidase; MPO, myeloperoxidase; POR, 
NADPH:cytochrome P450 oxidoreductase; R = -COCH3 or -SO3H.   
Fig. 2. Induction of CYP1A1 (A,B) and NQO1 (C,D) in kidneys (A,C) and lungs (B,D) of 
rats treated with 0.4, 4 or 40 mg/kg bw of 3-ABA determined by Western blots as 
described in Material and methods. Immunoblots of microsomal CYP1A1 and 
cytosolic NQO1 from untreated and 3-NBA-treated rats stained with antibody 
against rat CYP1A1 and human NQO1. Values represent mean ± S.D. obtained from 
lungs and kidneys of three rats (n=3). Values significantly different from control: 
*p<0.05, **p<0.01, ***p<0.001 (Student’s t-test). 
Fig. 3. Autoradiographic profiles of DNA adducts generated (A) by 3-NBA after its 
activation with cytosols isolated from lungs of rats treated with 40 mg/kg bw of 3-
ABA and NADPH, and (B) by 3-ABA after its activation with microsomes isolated 
from kidneys of rats treated with 40 mg/kg bw of 3-ABA and NADPH by using the 
butanol enrichment version of the 32P-postlabelling assay. Spot 1 = dA-N6-ABA, 
spot 3 = dG-N2-ABA, spots 4/5 = dG-C8-N-ABA.  
Fig. 4. DNA adduct formation by 3-NBA activated with cytosols isolated from kidneys and 
lungs of rats, control (uninduced) or pretreated with 40 mg/kg bw of 3-ABA, using 
different cofactors. See text for details. F = fold increase in DNA adduct levels in 
cytosols from 3-ABA-treated rats compared to control (uninduced) rats. Mean ± S.E. 
shown in the figure represent total levels of DNA adducts (RAL, relative adduct 
labelling) of three determinations. *p<0.05, **p<0.01 (Student’s t-test). 
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Fig. 5. DNA adduct formation by 3-ABA activated with microsomes isolated from kidneys 
and lungs of rats, control (uninduced) or pretreated with 40 mg/kg bw of 3-ABA, 
using different cofactors.  F = fold increase in DNA adducts levels in microsomes 
from 3-ABA-treated rats compared to control (uninduced) rats. Mean ± S.E. shown 
in the figure represent total DNA adduct levels (RAL, relative adduct labelling) of 
three determinations. None = without cofactor; AA = arachidonic acid. ND = not 
detected. *p<0.05, **p<0.01, ***p<0.001 (Student’s t-test). 
Fig. 6. DNA adduct formation by 3-ABA activated with cytosols isolated from kidneys and 
lungs of rats, control (uninduced) or pretreated with 40 mg/kg bw of 3-ABA, using 
hydrogen peroxide as a cofactor. Mean ± S.E. shown in the figure represent total 
DNA adduct levels (RAL, relative adduct labelling) of three determinations. None = 
without cofactor; ND = not detected.  *p<0.05 (Student’s t-test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
31
31
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
50
100
150
200
250
300
350
400
0 0,4 4 40 0
mg of 3-ABA/kg                                          mg of 3-ABA/kg
CY
P1
A
1 
(%
)
A B 
** 
*** 
 
0
20
40
60
80
100
120
140
160
0 0,4 4 40
mg of 3-ABA/kg                                          mg of 3-ABA/kg
N
QO
1 
(%
)
0,4 4 40
DC 
* 
*** 
*** *** 
32
32
 
0 0,4 4 40
 
* * 
  
33
33
  
 
 
 
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
2 
1 
3 
4 
A 1 
5 
2 
3 
4 
B 
  
34
34
 
 
 
 
 
 
 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                        
                                        
                                        
                                        
                                        
                                        
NADPH NADPH+PAPS NADPH + Acetyl CoA
0
2
4
6
8
10
50
100
150
200
*
*
*
F = 1.3
F = 1.2
F = 1.2
Kidney
R
AL
 
pe
r 
10
8  
n
u
cl
e
o
tid
e
s
 rat control cytosol
 rat 3-ABA cytosol
                                        
                                        
                                        
                                        
                                        
                                        
NADPH NADPH+PAPS NADPH + Acetyl CoA
0
2
4
6
8
10
50
100
150
200
**
**
*
F = 1.7
F = 1.6
F = 1.5
Lung
R
AL
 
pe
r 
10
8  
n
u
cl
e
o
tid
e
s
 rat control cytosol
 rat 3-ABA cytosol
  
35
35
 
 
Figure 5 
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Figure 6 
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Supporting Table S1.  
a) Effect of enzyme cofactors on DNA adduct formation by 3-ABA in rat kidney cytosol 
from control rats or rats treated with 40 mg 3-ABA/kg bw 
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced kidney cytosol  
without cofactor 
0.148 ± 
0.013 
0.310 ± 
0.289 
0.823 ± 
0.754 
0.449 ± 
0.398 
0.066 ± 
0.010 
1.796 ± 
0.154 
uninduced kidney cytosol + 
NADPH  
0.467 ± 
0.051 
0.698 ± 
0.061 
1.797 ± 
0.142 
1.483 ± 
0.132 
0.392 ± 
0.034 
4.82 ± 
0.360 
       
       
uninduced kidney cytosol + 
NADPH + PAPS 
0.749 ± 
0.064 
1.369 ± 
0.327 
2.978 ± 
0.234 
3.061 ± 
0.300 
0.583 ± 
0.052 
8.74 ± 
0.782 
uninduced kidney cytosol + 
NADPH + acetylCoA 
12.80 ± 
1.001 
38.63 ± 
3.123 
43.65 ± 
4.176 
46.61 ± 
4.101 
1.38 ± 
0.151 
143.08 ± 
11.201 
3-ABA kidney cytosol + 
NADPH 
0.561 ± 
0.102 
0.838 ± 
0.140 
2.156 ± 
0.189 
1.779 ± 
0.152 
0.470 ± 
0.038 
5.804 ± 
0.487 
3-ABA kidney cytosol + 
NADPH + PAPS 
0.899 ± 
0.087 
1.643 ± 
0.101 
3.584 ± 
0.265 
3.673 ± 
0.301 
0.699 ± 
0.098 
10.498 ± 
1.021 
3-ABA kidney cytosol + 
NADPH + acetylCoA 
17.92 ± 
1.24 
54.082 
± 4.254 
61.11 ± 
5.877 
62.254 
± 5.989 
1.932 ± 
0.241 
197.298 ± 
18.142 
 
b) Effect of enzyme cofactors on DNA adduct formation by 3-ABA in rat lung cytosol 
from control rats or rats treated with 40 mg 3-ABA/kg bw 
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced lung cytosol  without 
cofactor 
0.084 ± 
0.011 
0.054 ± 
0.009 
0.151 ± 
0.012 
0.075 ± 
0.010 
0.074 ± 
0.010 
0.443 ± 
0.034 
uninduced lung cytosol + 
NADPH  
0.189 ± 
0.015 
0.298 ± 
0.021 
1.210 ± 
0.102 
0.882 ± 
0.068 
0.110 ± 
0.011 
2.688 ± 
0.190 
       
       
uninduced lung cytosol + 
NADPH + PAPS 
0.511 ± 
0.048 
0.977 ± 
0.101 
1.989 ± 
0.132 
1.989 ± 
0.165 
0.386 ± 
0.030 
5.852 ± 
0.476 
uninduced lung cytosol + 
NADPH + acetylCoA 
5.13 ± 
0.498 
7.71 ± 
0.671 
13.88 ± 
1.151 
17.826 
± 1.482 
3.712 ± 
0.301 
48.656 
± 4.426 
3-ABA lung cytosol + NADPH 0.284 ± 
0.020 
0.447 ± 
0.032 
1.815 ± 
0.121 
1.323 ± 
0.087 
0.165 ± 
0.081 
4.034 ± 
0.395 
3-ABA lung cytosol + NADPH 
+ PAPS 
0.818 ± 
0.067 
1.563 ± 
0.078 
3.182 ± 
0.201 
3.182 ± 
0.198 
0.618 ± 
0.061 
9.363 ± 
0.712 
3-ABA lung cytosol + NADPH 
+ acetylCoA 
8.208 ± 
0.802 
12.336 
± 1.214 
22.208 
± 2.010 
28.522 
± 2.351 
10.740 ± 
0.910 
82.014 
± 7.132 
 
a Mean ± S.E. (RAL, relative adduct labelling) of triplicate in-vitro incubations; spot 1 = 
dA-N6-ABA, spot 3 = dG-N2-ABA, spots 4/5 = dG-C8-N-ABA. 
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Supporting Table S2.  
a) DNA adduct formation by 3-ABA activated by kidney microsomes of rats either 
uninduced or induced with 40 mg 3-ABA/kg bw 
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced without cofactor 
 
uninduced s + NADPH 
 
 
uninduced + arachidonic acid 
 
NDb 
 
0.067 ± 
0.007 
 
0.055 ± 
0.006 
ND 
 
0.087 ± 
0.009 
 
0.096 ± 
0.010 
ND 
 
0.377 ± 
0.032 
 
0.197 ± 
0.018 
ND 
 
0.154 ± 
0.014 
 
0.088 ± 
0.003 
 
ND 
 
0.025 ± 
0.003 
 
ND 
 
 
ND 
 
0.710 ± 
0.078 
 
0.436 ± 
0.045 
 
3-ABA microsomes without 
cofactor 
3-ABA microsomes + NADPH  
 
 
3-ABA microsomes + 
arachidonic acid 
ND 
 
0.302 ± 
0.019 
 
0.066 ± 
0.010 
ND 
 
0.392 ± 
0.030 
 
0.115 ± 
0.011 
ND 
 
1.697 ± 
0.010 
 
0.237 ± 
0.021 
ND 
 
0.693± 
0.0541 
 
0.106 ± 
0.010 
ND 
 
0.112 ± 
0.010 
 
ND 
 
ND 
 
3.196 ± 
0.257 
 
0.524 ± 
0.051 
       
b) DNA adduct formation by 3-ABA activated by lung microsomes of rats either 
uninduced or induced with 40 mg 3-ABA/kg bw 
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced lung microsomes 
without cofactor 
uninduced lung microsomes + 
NADPH 
 
uninduced lung microsomes + 
arachidonic acid 
NDb 
 
0.072 ± 
0.008 
 
0.035 ± 
0.004 
ND 
 
0.062 ± 
0.006 
 
0.035 ± 
0.004 
ND 
 
0.154 ± 
0.012 
 
0.101 ± 
0.010 
ND 
 
0.059 ± 
0.004 
 
0.026 ± 
0.003 
ND 
 
0.055 ± 
0.005 
 
0.026 ± 
0.003 
ND 
 
0.402 ± 
0.037 
 
0.223 ± 
0.025 
3-ABA lung microsomes 
without cofactor 
3-ABA lung microsomes + 
NADPH  
 
3-ABA lung microsomes + 
arachidonic acid 
ND 
 
0.202 ± 
0.011 
 
0.042 ± 
0.004 
ND 
 
0.174 ± 
0.013 
 
0.043 ± 
0.004 
ND 
 
0.431 ± 
0.035 
 
0.121 ± 
0.011 
ND 
 
0.165± 
0.015 
 
0.032 ± 
0.011 
ND 
 
0.154 ± 
0.012 
 
0.031 ± 
0.003 
ND 
 
1.126 ± 
0.101 
 
0.269 ± 
0.020 
       
a Mean ± S.E. (RAL, relative adduct labelling) of triplicate in-vitro incubations; spot 1 = 
dA-N6-ABA, spot 3 = dG-N2-ABA, spots 4/5 = dG-C8-N-ABA. 
b ND = not detected. 
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Supporting Table S3.  
a) DNA adduct formation by 3-ABA activated by kidney cytosols of rats either 
uninduced or induced with 40 mg 3-ABA/kg bw 
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced  
cytosol  
NDb ND ND ND ND ND 
uninduced  
cytosol + H2O2 
0.237± 
0.023 
0.233 ± 
0.023 
 
0.272 ± 
0.029 
 
0.163 ± 
0.014 
 
ND  0.905 ± 
0.110 
3-ABA  
cytosol + H2O2 
0.309 ± 
0.032 
0.303 ± 
0.025 
0.354 ± 
0.031 
0.212± 
0.020 
ND 1.178 ± 
0.102 
 
 
b) DNA adduct formation by 3-ABA activated by lung cytosols of rats either uninduced 
or induced with 40 mg 3-ABA/kg bw 
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced  
cytosol  
NDb ND ND ND ND ND 
uninduced  
cytosol + H2O2 
0.057± 
0.007 
0.072 ± 
0.008 
 
0.128 ± 
0.015 
 
0.066 ± 
0.008 
 
0.060 ± 
0.007 
 
0.383 ± 
0.045 
3-ABA  
cytosol + H2O2 
0.090 ± 
0.010 
0.087 ± 
0.010 
0.166± 
0.011 
0.110 ± 
0.012 
0.090 ± 
0.010 
0.543 ± 
0.051 
 
 
 
a Mean ± S.E. (RAL, relative adduct labelling) of triplicate in-vitro incubations; spot 1 = 
dA-N6-ABA, spot 3 = dG-N2-ABA, spots 4/5 = dG-C8-N-ABA. 
b ND = not detected. 
 
 
 
 
 
 
 
 
 
